Literature DB >> 26008896

Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation.

Oliver Dörr1, Sebastian Ewen2, Christoph Liebetrau3,4, Helge Möllmann3,4, Luise Gaede3,4, Dominik Linz2, Mathias Hohl2, Christian Troidl3,4, Timm Bauer5, Michael Böhm2, Christian Hamm5,3, Felix Mahfoud2,6, Holger Nef5.   

Abstract

BACKGROUND: Renal sympathetic denervation (RSD) represents a safe and effective treatment option for certain patients with resistant hypertension and has been shown to decrease sympathetic activity. Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up-regulated during increased sympathetic activity. The aim of the present study was to examine the effect of RSD on NPY and to analyze the association between changes in NPY levels and blood pressure reduction after RSD.
METHODS: A total of 150 consecutive patients (age 64.9 ± 10.2 years) from three clinical centers undergoing RSD were included in this study. Response to RSD was defined as an office systolic blood pressure (SBP) reduction of >10 mmHg 6 months after RSD. Venous blood samples for measurement of NPY were collected prior to and 6 months after RSD.
RESULTS: BP and NPY levels were significantly reduced by 23/9 mmHg (p = 0.001/0.001) and 0.24 mg/dL (p < 0.01) 6 months after RSD. There was a significant correlation between baseline SBP- and RSD-related systolic BP reduction (r = -0.43; p < 0.001) and between serum NPY baseline values and NPY level changes (r = -0.52; p < 0.001) at the 6-month follow-up. The BP response to RSD (>10 mmHg) was associated with a significantly greater reduction in NPY level when compared with BP non-responders (p = 0.001).
CONCLUSION: This study demonstrates an effect of RSD on serum NPY levels, a specific marker for sympathetic activity. The association between RSD-related changes in SBP and NPY levels provides further evidence of the effect of RSD on the sympathetic nervous system.

Entities:  

Keywords:  Hypertension; Procedural success; Renal sympathetic denervation

Mesh:

Substances:

Year:  2015        PMID: 26008896     DOI: 10.1007/s00392-015-0874-8

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  37 in total

1.  Radioimmunoassay for plasma neuropeptide-Y in physiological and physiopathological states and response to sympathetic activation.

Authors:  M A Miller; G A Sagnella; N D Markandu; G A MacGregor
Journal:  Clin Chim Acta       Date:  1990-11-15       Impact factor: 3.786

Review 2.  Renal denervation: effects on atrial electrophysiology and arrhythmias.

Authors:  Dominik Linz; Arne van Hunnik; Christian Ukena; Sebastian Ewen; Felix Mahfoud; Stephan H Schirmer; Matthias Lenski; Hans-Ruprecht Neuberger; Ulrich Schotten; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2014-03-29       Impact factor: 5.460

3.  Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans.

Authors:  M J Morris; H S Cox; G W Lambert; D M Kaye; G L Jennings; I T Meredith; M D Esler
Journal:  Hypertension       Date:  1997-01       Impact factor: 10.190

4.  Renal denervation for resistant hypertension.

Authors:  Vasilios Kotsis; Stella Stabouli
Journal:  N Engl J Med       Date:  2014-07-10       Impact factor: 91.245

Review 5.  Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.

Authors:  Murray Esler
Journal:  J Am Soc Hypertens       Date:  2014-06-12

6.  Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension.

Authors:  Dagmara Hering; Petra Marusic; Antony S Walton; Elisabeth A Lambert; Henry Krum; Krzysztof Narkiewicz; Gavin W Lambert; Murray D Esler; Markus P Schlaich
Journal:  Hypertension       Date:  2014-04-14       Impact factor: 10.190

7.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

8.  Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers.

Authors:  Ulla C Kopp; Michael Z Cicha; Lori A Smith; Jan Mulder; Tomas Hökfelt
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-08-15       Impact factor: 3.619

9.  Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.

Authors:  Felix Mahfoud; Christian Ukena; Roland E Schmieder; Bodo Cremers; Lars C Rump; Oliver Vonend; Joachim Weil; Martin Schmidt; Uta C Hoppe; Thomas Zeller; Axel Bauer; Christian Ott; Erwin Blessing; Paul A Sobotka; Henry Krum; Markus Schlaich; Murray Esler; Michael Böhm
Journal:  Circulation       Date:  2013-06-18       Impact factor: 29.690

10.  Sympatho-renal axis in chronic disease.

Authors:  Paul A Sobotka; Felix Mahfoud; Markus P Schlaich; Uta C Hoppe; Michael Böhm; Henry Krum
Journal:  Clin Res Cardiol       Date:  2011-06-19       Impact factor: 5.460

View more
  10 in total

Review 1.  Modulation of renal sympathetic innervation: recent insights beyond blood pressure control.

Authors:  Dominik Linz; Mathias Hohl; Adrian D Elliott; Dennis H Lau; Felix Mahfoud; Murray D Esler; Prashanthan Sanders; Michael Böhm
Journal:  Clin Auton Res       Date:  2018-02-10       Impact factor: 4.435

2.  Second denervation in a patient with resistant hypertension.

Authors:  Jose Carlos Prado; Dayan Salado; Luis Miguel Ruilope; Julian Segura
Journal:  Clin Res Cardiol       Date:  2016-06-08       Impact factor: 5.460

3.  Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial.

Authors:  Karl Fengler; Diana Heinemann; Thomas Okon; Karoline Röhnert; Thomas Stiermaier; Maximilian von Röder; Christian Besler; Ulrike Müller; Robert Höllriegel; Gerhard Schuler; Steffen Desch; Philipp Lurz
Journal:  Clin Res Cardiol       Date:  2016-01-04       Impact factor: 5.460

Review 4.  Renal Denervation: Is It Ready for Prime Time?

Authors:  Lucas Lauder; Milan A Wolf; Sean S Scholz; Mathias Hohl; Felix Mahfoud; Michael Böhm
Journal:  Curr Cardiol Rep       Date:  2019-07-05       Impact factor: 2.931

Review 5.  Renal sympathetic denervation in therapy resistant hypertension - pathophysiological aspects and predictors for treatment success.

Authors:  Karl Fengler; Karl Philipp Rommel; Thomas Okon; Gerhard Schuler; Philipp Lurz
Journal:  World J Cardiol       Date:  2016-08-26

6.  Erythrocyte Salt Sedimentation Assay Does Not Predict Response to Renal Denervation.

Authors:  Oliver Vonend; Ole Martin; Lars C Rump; Patrick Kroepil; Johannes Stegbauer
Journal:  Front Med (Lausanne)       Date:  2018-03-09

7.  A role for NPY-NPY2R signaling in albuminuric kidney disease.

Authors:  Abigail C Lay; A Fern Barrington; Jenny A Hurcombe; Raina D Ramnath; Mark Graham; Philip A Lewis; Marieangela C Wilson; Kate J Heesom; Matthew J Butler; Rebecca M Perrett; Chris R Neal; Eleanor Herbert; Edward Mountjoy; Denize Atan; Viji Nair; Wenjun Ju; Robert G Nelson; Matthias Kretzler; Simon C Satchell; Craig A McArdle; Gavin I Welsh; Richard J M Coward
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-19       Impact factor: 11.205

8.  A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model.

Authors:  Lucas Lauder; L Boyce Moon; Catherine A Pipenhagen; Sebastian Ewen; Jeffrey M Fish; Renu Virmani; James A Jensen; Michael Böhm; Felix Mahfoud
Journal:  Clin Res Cardiol       Date:  2020-11-02       Impact factor: 6.138

Review 9.  Neuropeptide Y and Metabolism Syndrome: An Update on Perspectives of Clinical Therapeutic Intervention Strategies.

Authors:  Yinqiong Huang; Xiahong Lin; Shu Lin
Journal:  Front Cell Dev Biol       Date:  2021-07-09

10.  Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges.

Authors:  Carmine Zoccali; Alberto Ortiz; Inga Arune Blumbyte; Sarina Rudolf; Annette G Beck-Sickinger; Jolanta Malyszko; Goce Spasovski; Sol Carriazo; Davide Viggiano; Justina Kurganaite; Vaiva Sarkeviciene; Daiva Rastenyte; Andreja Figurek; Merita Rroji; Christopher Mayer; Mustapha Arici; Gianvito Martino; Gioacchino Tedeschi; Annette Bruchfeld; Belinda Spoto; Ivan Rychlik; Andrzej Wiecek; Mark Okusa; Giuseppe Remuzzi; Francesca Mallamaci
Journal:  Nephrol Dial Transplant       Date:  2021-12-28       Impact factor: 5.992

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.